- Conditions
- Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
- Interventions
- Litifilimab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 62
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Enpatoran
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Billerica, Massachusetts
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- CC-11050, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Interventions
- Skin biopsy, Blood collection, Urine collection
- Procedure
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 9
- States / cities
- La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
- Interventions
- Enpatoran, Placebo, Standard of care (SoC)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- M5049 low dose, M5049 medium dose, M5049 high dose, Placebo
- Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 8
- States / cities
- Torrance, California • Brandon, Florida • Miami, Florida + 5 more
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Interventions
- R932333, Placebo
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Torrance, California • Brandon, Florida • Miami, Florida + 10 more
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
- Interventions
- Deucravacitinib, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- CC-10004
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
- Interventions
- Tofacitinib citrate
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Quinacrine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Victoria Werth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
- Interventions
- AMG811, AMG811 Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
- Conditions
- Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
- Interventions
- Afimetoran, Placebo
- Drug
- Lead sponsor
- Beeline Medicines Corporation
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • DeBary, Florida • Missoula, Montana
- Conditions
- Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
- Interventions
- Skin Taping, Blood Sampling, Skin Biopsy
- Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Discoid Lupus
- Interventions
- CC-930, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- SAR443122, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Cooper City, Florida • Charlotte, North Carolina • Columbus, Ohio + 1 more
- Conditions
- Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Interventions
- BMS-986165
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
- Conditions
- Discoid Lupus Erythematosus (DLE)
- Interventions
- etanercept(Enbrel®)
- Drug
- Lead sponsor
- Florida Academic Dermatology Centers
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Enpatoran, Placebo, Standard of care (SoC)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Thousand Oaks, California • Cooper City, Florida + 7 more
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Placebo, Daxdilimab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- North Little Rock, Arkansas • Beverly Hills, California • Fremont, California + 12 more